NEW YORK (GenomeWeb) – After completing its first quarter as a public company, Salt Lake City, Utah-based Co-Diagnostics on Wednesday reported Q3 revenues of $2,598 compared to no revenue in the prior-year quarter.

For the three-month period ended Sept. 30, the firm's net loss grew to $3.9 million, or $.33 per share, from a loss of $449,950, or $.05 per share, in Q3 2016.

The firm's R&D expenses for the quarter rose 58 percent to $272,209 from $172,804 in Q3 2016, while SG&A expenses grew sevenfold to $1.5 million from $212,253.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.